A Phase II Study of Sunitinib Malate in Patients With Renal Cell Carcinoma and Unresectable Primary Tumors.
Phase of Trial: Phase II
Latest Information Update: 05 May 2014
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 06 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 15 Oct 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
- 15 Oct 2012 Planned End Date changed from 1 Dec 2012 to 1 Mar 2011 as reported by ClinicalTrials.gov.